Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00828932
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT00794781
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT00784303
Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00760084
- Locations
- ๐บ๐ธ
Washington University School of Medicine, St. Louis, Missouri, United States
A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00756912
- Locations
- ๐บ๐ธ
Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT00754052
- Locations
- ๐บ๐ธ
Road Runner Research, San Antonio, Texas, United States
๐บ๐ธNeuroscience, Inc, Herndon, Virginia, United States
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00754013
- Locations
- ๐บ๐ธ
Road Runner Research, San Antonio, Texas, United States
๐บ๐ธNeuroScience, Inc., Herndon, Virginia, United States
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1218
- Registration Number
- NCT00735397
Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
Phase 4
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2008-07-08
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT00711204
- Locations
- ๐บ๐ธ
Kettlie Joseph Daniels, M.D. Inc., Toledo, Ohio, United States
Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00706095
- Locations
- ๐ณ๐ฑ
Utrecht Medical Centre, Utrecht, Netherlands
๐ณ๐ฑNetherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
ยฉ Copyright 2024. All Rights Reserved by MedPath